Evidence-based Pharmaceutical Practice Responding for Novel Coronavirus Pneumonia Epidemic
- VernacularTitle:新型冠状病毒肺炎疫情应对的循证药学实践
- Author:
Zhanmiao YI
1
,
2
;
Hao GUO
1
,
3
;
Shibo QI
1
,
4
;
Tiantian ZHOU
1
,
5
;
Rongsheng ZHAO
1
Author Information
1. Dept. of Pharmacy，Peking University Third Hospital，Beijing 100191，China
2. Institute for Drug Evaluation，Peking University Health Science Center，Beijing 100191，China
3. Dept. of Pharmacy，Inner Mongolia Autonomous Region People’s Hospital，Hohhot 010017，China
4. Dept. of Pharmacy，Liaoning Health Industry Group Bengang General Hospital，Liaoning Benxi 117000，China
5. Dept. of Pharmaceutical Affairs，Zhengzhou Second People’s Hospital，Zhengzhou 450000，China
- Publication Type:Journal Article
- Keywords:
Evidence-based pharmacy;
Novel coronavirus;
Pharmaceutical information;
Medical treatment;
Drug interactions
- From:
China Pharmacy
2020;31(5):527-531
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE：To p rovide reference for related pharmacy work for developing evidence-based pharmacy information support to respond for novel coronavirus pneumonia （COVID-19） epidemic. METHODS ：The PubMed，CNKI and Wanfang database were consulted to obtain treatment progress of COVID-19，prohibited for use with lopinavir/ritonavir and adverse drug reactionas until February 12，2020；so were package insert and UpToDate at the same time. Those information were summarized and evaluated. RESULTS & CONCLUSIONS ：Totally 14 literatures introduced chemical drugs for COVID- 19，involving 7 categories， 20 kinds of chemical drugs as antiviral drugs （interferon α/interferon α-2 β ， lopinavir/litonavir， etc.）， immunomodulatory agents （such as glucocorticoid ，gamma globulin ），antimalarial drugs （such as chloroquine phosphate ）. The existing evidence of drug treatment mainly comes from in vitro cell test or currently progressing RCT ，with low-level evidence and recommendation intensity （Oxford evidence level is level 5，recommendation intensity is level D ）. For lopinavir/ritonavir that recommended in the diagnosis and treatment recommendations for COVID- 19 published by the National Health Commission ，it is a CYP3A inhibitor ，which resulted in increased plasma concentrations of some medications such as antiarrhythmic drugs ，antitumor targeted drugs and antibacterial drugs ，and should not be used in combination with drugs such as afzosin ，ivabradine，amiodarone， etc. Its common adverse reactions mainly involved igestive system （diarrhea，taste disorders ，vomiting，etc.），respiratory system （upper respiratory tract infection ），endocrine and metabolic system （hypercholesterolemia，etc.），skin and its appendents （skin rash），which should be monitored clinically.
